{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=21",
    "query": {
      "intervention": "Saline 0.9%",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 1512,
    "total_pages": 152,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T01:54:10.780Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03483363",
      "title": "Topical Antibiotic Irrigation (Gentamicin) in Prophylaxis of Midfacial Fracture Surgical Wounds",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Surgical Site Infection"
      ],
      "interventions": [
        {
          "name": "topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)",
          "type": "DRUG"
        },
        {
          "name": "topical irrigation with sterile normal saline (NS)",
          "type": "DRUG"
        },
        {
          "name": "intravenous (IV) prophylactic antibiotic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2018-10-09",
      "completion_date": "2022-01-02",
      "has_results": true,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-10-22T01:54:10.780Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03483363"
    },
    {
      "nct_id": "NCT04640038",
      "title": "Contrast Enhanced Ultrasound in COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19",
        "Multisystem Inflammatory Syndrome in Children (MIS-C)"
      ],
      "interventions": [
        {
          "name": "Sulfur hexafluoride lipid-type A microspheres",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Minute to 17 Years"
      },
      "enrollment_count": 4,
      "start_date": "2020-12-18",
      "completion_date": "2021-09-17",
      "has_results": true,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-10-22T01:54:10.780Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04640038"
    },
    {
      "nct_id": "NCT00128193",
      "title": "Leprosy Skin Test Antigens Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leprosy"
      ],
      "interventions": [
        {
          "name": "Tuberculin, Purified Protein Derivative",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MLSA-LAM",
          "type": "OTHER"
        },
        {
          "name": "MLCwA",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 260,
      "start_date": "2002-04",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2014-12-24",
      "last_synced_at": "2026-10-22T01:54:10.780Z",
      "location_count": 1,
      "location_summary": "Fort Collins, Colorado",
      "locations": [
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00128193"
    },
    {
      "nct_id": "NCT02292784",
      "title": "Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obstetric Labour, Premature"
      ],
      "interventions": [
        {
          "name": "Retosiban",
          "type": "DRUG"
        },
        {
          "name": "Atosiban",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Weeks",
        "maximum_age": "20 Weeks",
        "sex": "ALL",
        "summary": "10 Weeks to 20 Weeks"
      },
      "enrollment_count": 98,
      "start_date": "2015-06-01",
      "completion_date": "2019-09-02",
      "has_results": true,
      "last_update_posted_date": "2020-07-09",
      "last_synced_at": "2026-10-22T01:54:10.780Z",
      "location_count": 2,
      "location_summary": "Park Ridge, Illinois • Galveston, Texas",
      "locations": [
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02292784"
    },
    {
      "nct_id": "NCT02337855",
      "title": "A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schistosomiasis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Sm-TSP-2/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sm-TSP-2/Alhydrogel/GLA-AF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 72,
      "start_date": "2015-02-04",
      "completion_date": "2017-01-27",
      "has_results": false,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-10-22T01:54:10.780Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02337855"
    },
    {
      "nct_id": "NCT01683955",
      "title": "Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Blood Loss Anemia",
        "Osteoarthritis, Hip"
      ],
      "interventions": [
        {
          "name": "Tranexamic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2013-01-01",
      "completion_date": "2013-11-03",
      "has_results": false,
      "last_update_posted_date": "2023-04-03",
      "last_synced_at": "2026-10-22T01:54:10.780Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01683955"
    },
    {
      "nct_id": "NCT04510428",
      "title": "OSIG-eye Drops Treatment for Dry Eye Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Ocular Surface Immune Globulin (OSIG)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-05-15",
      "completion_date": "2024-01-20",
      "has_results": false,
      "last_update_posted_date": "2023-05-23",
      "last_synced_at": "2026-10-22T01:54:10.780Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04510428"
    },
    {
      "nct_id": "NCT02960581",
      "title": "Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "PGT121 3mg/kg IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGT121 10mg/kg IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGT121 30mg/kg IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGT121 3mg/kg SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% Sodium Chloride Injection USP (Saline))",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2016-11",
      "completion_date": "2019-07-08",
      "has_results": false,
      "last_update_posted_date": "2019-09-17",
      "last_synced_at": "2026-10-22T01:54:10.780Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02960581"
    },
    {
      "nct_id": "NCT01673828",
      "title": "Allopregnanolone for the Treatment of Traumatic Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Traumatic Brain Injury",
        "Posttraumatic Epilepsy"
      ],
      "interventions": [
        {
          "name": "Allopregnanolone injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael A. Rogawski, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-04",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2017-06-28",
      "last_synced_at": "2026-10-22T01:54:10.780Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01673828"
    },
    {
      "nct_id": "NCT07489430",
      "title": "DaxibotulinumtoxinA for Blepharospasm",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blepharospasm of Both Eyelids",
        "Blepharospasm of Left Eyelid",
        "Blepharospasm of Right Eyelid",
        "Blepharospasm, Benign Essential",
        "Blepharospasm"
      ],
      "interventions": [
        {
          "name": "Botulinum Neurotoxin Type A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-09-24",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-22T01:54:10.780Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07489430"
    }
  ]
}